|
1
|
Ramdani HO, Falk M, Heukamp LC, Schatz S, Tiemann M, Wesseler C, Diehl L, Schuuring E, Groen HJM, Griesinger F. Immune related endonucleases and GTPases are not associated with tumor response in patients with advanced non-small cell lung cancer treated with checkpoint inhibitors. Pathol Res Pract 2021; 227:153651. [PMID: 34673351 DOI: 10.1016/j.prp.2021.153651] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/10/2021] [Revised: 09/30/2021] [Accepted: 10/06/2021] [Indexed: 10/20/2022]
Abstract
Immune related endonucleases have recently been described as potential therapeutic targets and predictors of response to treatment with immune checkpoint inhibitors (ICI). The aim is to evaluate the association between the expression of 5 biomarkers involved in the immune response (CD73, CD39, VISTA, Arl4d and Cytohesin-3) in parallel with the more common ICI-predictive markers, PD-L1 expression and Tumor Mutation Burden (TMB) with response to ICI therapy in an advanced non-small cell lung cancer (NSCLC) cohort. METHODS Patients with advanced NSCLC treated with ICI single agent were divided into responders and non-responders according to RECIST v1.1 and duration of response (DOR) criteria. Immunohistochemistry was performed on pretreatment tumor tissue samples for PD-L1, CD73, CD39, VISTA, Arl4d, and Cytohesin-3 expression. TMB was estimated with NEOplus v2 RUO (NEO New Oncology GmbH) hybrid capture next generation sequencing assay. Resistance mutations in STK11/KEAP1 and positive predictive mutations in ARID1A/POLE were also evaluated. RESULTS Included were 56 patients who were treated with ICI single agent. The median progression-free and overall survival for the whole cohort was 3.0 (95% CI, 2.4-3.6) and 15 (95% CI, 9.7-20.2) months, respectively. The distribution of CD73 in tumor cells and CD39, VISTA, Arl4d and Cytohesin-3 expression in immune cells were not different between responders and non-responders. Also, PD-L1 and TMB were not predictive for response. The frequency of STK11, KEAP1 and ARID1A mutations was low and only observed in the non-responder group. CONCLUSION Separate and combined expression of 5 biomarkers involved in the immune response (CD73, CD39, VISTA, Arl4d, and Cytohesin-3) was not associated with response in our cohort of advanced NSCLC patients receiving single agent ICI. To confirm our findings the analysis of independent larger cohorts is warranted.
Collapse
Affiliation(s)
- H O Ramdani
- Departments of Pulmonary Diseases and Pathology, University of Groningen and University Medical Center Groningen, Hanzeplein 1, p.o. Box 30.000, 9700 RB Groningen, Netherlands; Dept. Hematology and Oncology, Pius-Hospital, University Dept. Internal Medicine-Oncology, Carl von Ossietzky University of Oldenburg, Germany.
| | - M Falk
- Institut für Hämatopathologie Hamburg, Fangdieckstraße 75A, 22547 Hamburg, Germany.
| | - L C Heukamp
- Institut für Hämatopathologie Hamburg, Fangdieckstraße 75A, 22547 Hamburg, Germany.
| | - S Schatz
- Institut für Hämatopathologie Hamburg, Fangdieckstraße 75A, 22547 Hamburg, Germany.
| | - M Tiemann
- Institut für Hämatopathologie Hamburg, Fangdieckstraße 75A, 22547 Hamburg, Germany.
| | - C Wesseler
- Department of Internal Medicine and Pulmonology, Asklepios Klinikum Harburg, Eißendorfer Pferdeweg 52, 21075 Hamburg, Germany.
| | - L Diehl
- Institute of Experimental Immunology and Hepatology, University Medical Center Hamburg Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.
| | - E Schuuring
- Departments of Pulmonary Diseases and Pathology, University of Groningen and University Medical Center Groningen, Hanzeplein 1, p.o. Box 30.000, 9700 RB Groningen, Netherlands.
| | - H J M Groen
- Departments of Pulmonary Diseases and Pathology, University of Groningen and University Medical Center Groningen, Hanzeplein 1, p.o. Box 30.000, 9700 RB Groningen, Netherlands.
| | - F Griesinger
- Dept. Hematology and Oncology, Pius-Hospital, University Dept. Internal Medicine-Oncology, Carl von Ossietzky University of Oldenburg, Germany.
| |
Collapse
|
|
2
|
Griesinger F, Sebastian M, Brückl W, Hummel HD, Jaeschke B, Kern J, Schumann C, Wesseler C, Jänicke M, Fleitz A, Zacharias S, Hipper A, Groth A, Weichert W, Dörfel S, Petersen V, Schröder J, Wilke J, Eberhardt W, Thomas M. 1325P Checkpoint inhibitor monotherapy in potentially study-eligible or non-study-eligible NSCLC patients in the German CRISP registry real-world cohort (AIO-TRK-0315). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1926] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
|
3
|
Roeper J, Falk M, Tiemann M, Heukamp L, Wesseler C, Wiest G, Sackmann S, Ukena D, Griesinger F. P74.02 Treatment Patterns of EGFR mt+ NSCLC IV pts: Real World Data of the NOWEL Network. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
|
4
|
Ramdani H, Falk M, Schatz S, Heukamp L, Tiemann M, Wesseler C, Schuuring E, Groen H, Griesinger F. P33.20 Evaluation of Combined Biomarker of Response to Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.689] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
|
5
|
Shah R, Klotz L, Feißt M, Schneider M, Kriegsmann M, Ried M, Wesseler C, Christoph D, de Wit M, Jürgens J, Kopp HG, Wehler T, Reck M, Sackmann S, Waller C, Reinmuth N, Bischoff H, Winter H, Eichhorn M, Thomas M. 1912TiP NICITA: Nivolumab with chemotherapy in pleural mesothelioma after surgery. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1455] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
|
6
|
Roeper J, Falk M, Schatz S, Tiemann M, Wesseler C, Wiest G, Sackmann S, Ukena D, Griesinger F. Treatment patterns of EGFR mt+ NSCLC IV pts: Real-world data of the NOWEL network. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.055] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
|
7
|
Roeper J, Lueers A, Falk M, Schatz S, Tiemann M, Wesseler C, Wiest G, Sackmann S, Ukena D, Heukamp L, Griesinger F. Risk of not receiving second-line therapy is high in EGFR mt+ patients: Real-world data of certified lung cancer centers on treatment sequence in EGFR mt+ patients. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz063.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
|
8
|
Sagorny C, Wesseler C, Krämer D, von Döhren J. Assessing the diversity and distribution of Cephalothrix
species (Nemertea: Palaeonemertea) in European waters by comparing different species delimitation methods. J ZOOL SYST EVOL RES 2019. [DOI: 10.1111/jzs.12266] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Christina Sagorny
- Institute of Evolutionary Biology and Ecology; University of Bonn; Bonn Germany
| | - Carina Wesseler
- Institute of Evolutionary Biology and Ecology; University of Bonn; Bonn Germany
| | - Daria Krämer
- Institute of Evolutionary Biology and Ecology; University of Bonn; Bonn Germany
| | - Jörn von Döhren
- Institute of Evolutionary Biology and Ecology; University of Bonn; Bonn Germany
| |
Collapse
|
|
9
|
Roeper J, Falk M, Schatz S, Tiemann M, Wesseler C, Wiest G, Sackmann S, Ukena D, Heukamp L, Griesinger F. Risk of not receiving second-line therapy is high in EGFR mt+ pts: Real world data of certified lung cancer centers on treatment sequence in EGFR mt+ pts. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
|
10
|
Roeper J, Falk M, Schatz S, Tiemann M, Sackmann S, Ukena D, Wesseler C, Wiest G, Heukamp L, Griesinger F. P1.01-82 Risk of Not Receiving 2nd Line Therapy is High in EGFR mt+ pts: Real World Data of Certified Lung Cancer Centers on Treatment Sequence in EGFR mt+ pts. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.638] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
|
11
|
Roeper J, Netchaeva M, Lueers A, Falk M, Tiemann M, Wesseler C, Wiest G, Sackmann S, Ukena D, Griesinger F. 163P The influence of 2nd and 3rd generation TKI in EGFR mt+ and ALK+ patients on OS and PFS: Results of the NOWEL network. J Thorac Oncol 2018. [DOI: 10.1016/s1556-0864(18)30437-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
|
12
|
Roeper J, Netchaeva M, Lüers A, Schatz S, Falk M, Tiemann M, Neemann N, Heukamp LC, Wesseler C, Wiest GH, Sackmann S, Ukena D, Griesinger F. Impact on OS and PFS of 2nd and 3 rd Generation TKI in EGFR mt+ and ALK+ patients: Results of the NOWEL network. Pneumologie 2018. [DOI: 10.1055/s-0037-1619262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- J Roeper
- Universitätsklinik Innere Medizin – Onkologie, Pius Hospital, Carl von Ossietzky Universität Oldenburg
| | - M Netchaeva
- Pius Hopital Oldenburg, Universität Oldenburg
| | - A Lüers
- Pius Hopital Oldenburg, Universität Oldenburg
| | - S Schatz
- Institut für Hämatopathologie Hamburg
| | - M Falk
- Molekularpathologie, Hämatopathologie Hamburg
| | - M Tiemann
- Institut für Hämatopathologie Hamburg
| | | | | | - C Wesseler
- Lungenheilkunde (Pneumologie) im Thoraxzentrum, Asklepios Klinik Harburg
| | | | - S Sackmann
- Klinik für Pneumologie und Beatmungsmedizin, Klinikum Bremen-Ost gGmbH
| | - D Ukena
- Klinik für Pneumologie und Beatmungsmedizin, Klinikum Bremen-Ost gGmbH
| | - F Griesinger
- Department of Hematology and Oncology, University Hospital, Pius-Hospital Oldenburg
| |
Collapse
|
|
13
|
Pink I, Wesseler C, Petermann C, Schwarz S, Groß-Fengels W, Meierling S, Wiest GH. Immuncheckpointinhibition als Therapieoption bei einschmelzenden Nichtkleinzelligen Lungenkarzinomen. Pneumologie 2018. [DOI: 10.1055/s-0037-1619254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- I Pink
- Klinik für Atemwegs-, Lungen- und Thoraxmedizin, Asklepios Klinikum Harburg
| | - C Wesseler
- Klinik für Atemwegs-, Lungen- und Thoraxmedizin, Asklepios Klinikum Harburg
| | - C Petermann
- Klinik für Atemwegs-, Lungen- und Thoraxmedizin, Asklepios Klinikum Harburg
| | - S Schwarz
- Klinik für Atemwegs-, Lungen- und Thoraxmedizin, Asklepios Klinikum Harburg
| | | | - S Meierling
- Klinik für Atemwegs-, Lungen- und Thoraxmedizin, Thoraxchirurgie, Asklepios Klinikum Harburg
| | - GH Wiest
- Klinik für Atemwegs-, Lungen- und Thoraxmedizin, Asklepios Klinikum Harburg
| |
Collapse
|
|
14
|
Roeper J, Lueers A, Netchaeva M, Falk M, Hallas C, Tiemann M, Neemann N, Heukamp L, Wesseler C, Wiest G, Ukena D, Sackmann S, Griesinger F. Impact on OS and PFS of 2nd and 3rd generation TKI in EGFR mt+ and ALK+ pts: Results of the NOWEL network. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.061] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
|
15
|
Atug E, Petermann C, Schwarz S, Wesseler C, Gross-Fengels W, Meierling S, Wiest GH. Erfolgreiche interventionelle Embolisation einer schweren pulmonalen Blutung bei Pulmonalarterienagenesie mit ausgeprägter Kollateralbildung. Pneumologie 2017. [DOI: 10.1055/s-0037-1598511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- E Atug
- Klinik für Atemwegs-, Lungen- und Thoraxmedizin, Asklepios Klinikum Harburg
| | - C Petermann
- Klinik für Atemwegs-, Lungen- und Thoraxmedizin, Asklepios Klinikum Harburg
| | - S Schwarz
- Klinik für Atemwegs-, Lungen- und Thoraxmedizin, Asklepios Klinikum Harburg
| | - C Wesseler
- Klinik für Atemwegs-, Lungen- und Thoraxmedizin, Asklepios Klinikum Harburg
| | - W Gross-Fengels
- Abteilung für Diagnostische und Interventionelle Radiologie, Asklepios Klinikum Harburg
| | - S Meierling
- Klinik für Atemwegs-, Lungen- und Thoraxmedizin, Asklepios Klinikum Harburg
| | - GH Wiest
- Klinik für Atemwegs-, Lungen- und Thoraxmedizin, Asklepios Klinikum Harburg
| |
Collapse
|
|
16
|
Geuchen C, Wesseler C, Winzer HO, Gross-Fengels W, Wiest GH. Das maligne epitheloide Haemangioendotheliom (EHE) der Lunge – 2 Fälle einer seltenen Tumorentität ohne etablierte Therapiestandards. Pneumologie 2017. [DOI: 10.1055/s-0037-1598339] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- C Geuchen
- Klinik für Atemwegs-, Lungen- und Thoraxmedizin, Asklepios Klinikum Harburg
| | - C Wesseler
- Klinik für Atemwegs-, Lungen- und Thoraxmedizin, Asklepios Klinikum Harburg
| | - HO Winzer
- Institut für Pathologie, Mvz Hanse Histologikum, Hamburg
| | - W Gross-Fengels
- Abteilung für Diagnostische und Interventionelle Radiologie, Asklepios Klinikum Harburg
| | - GH Wiest
- Klinik für Atemwegs-, Lungen- und Thoraxmedizin, Asklepios Klinikum Harburg
| |
Collapse
|
|
17
|
Reck M, Rittmeyer A, Wesseler C, Kropf-Sanchen C, Goldman JW, Rosen LS, Wunderle L, Schmid-Bindert G, Chan EM, Tolcher AW, Patnaik A, Shapiro GI, Paz-Ares L. Design der JUNIPER Studie auf Grundlage der Phase 1 Daten zu Abemaciclib: Eine randomisierte Phase 3 Studie zum Vergleich von Abemaciclib versus Erlotinib bei NSCLC im Stadium IV mit nachgewiesener KRAS mutation. Pneumologie 2017. [DOI: 10.1055/s-0037-1598328] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- M Reck
- Lungenclinic Großhansdorf, Airway Research Center North (Arcn), Member of the German Center for Lung Research (Dzl)
| | | | | | | | | | - LS Rosen
- Ucla Medical Center, Santa Monica
| | | | | | - EM Chan
- Eli Lilly and Company, Indianapolis
| | - AW Tolcher
- South Texas Accelerated Research Therapeutics, San Antonio
| | - A Patnaik
- Dana Farber Cancer Institute, Boston
| | | | | |
Collapse
|
|
18
|
Gökce-Gün D, Petermann C, Wesseler C, Wiest GH, Gross-Fengels W, Meierling S. PET – positive Herde beidseits: Oligo – metastasiert? Synchrone/Metachrone Bronchialkarzinome? Pneumologie 2017. [DOI: 10.1055/s-0037-1598266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
| | | | - C Wesseler
- Lungenheilkunde (Pneumologie) im Thoraxzentrum, Asklepios Klinik Harburg
| | | | | | | |
Collapse
|
|
19
|
Menon R, Mueller J, Lakis S, Hube A, Bochtler T, Wesseler C, Griesinger F, Loeffler H, Langenbuch T, Brandts C, Garcia A, Krämer A, Heuckmann J, Heukamp L. Identification of therapeutically targetable genomic alterations in a cohort of patients with CUP using a hybrid-capture based next generation sequencing assay. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)32751-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|